FCRL5 and neoplasm: In addition, other tumor antigens such G-protein-coupled receptor class C group 5 member D (GPRC5D), signaling lymphocyte activation molecular family 7 (SLAMF7), CD38, CD138, CD229, Fc receptor-homolog 5 (FcRH5), or a proliferation-inducing ligand (APRIL) are being tested as potential CAR T targets, and some of them have progressed from preclinical studies to early phase clinical trials, showing promising initial results [94,95].